



Name of entity: Ascent Pharmahealth Limited
(formerly Geneparm Australasia Limited)

ABN: 52 107 340 367

Release to the Market

Results and Preliminary Final Report (Appendix 4E)

For the financial year ended 30 June 2008

**For all media
enquiries:**

Dennis Bastas, CEO & Managing Director
+61 3 9699 2300

ASX Listing Rule 4.3A

1. Financial year ended		- Current Period	30 June 2008		
		- Prior period	30 June 2007		
2. Results for announcement to the market					
			%/\$000's from previous period		A\$'000
2.1	Sales Revenues from continuing operations	up	20 %	to	\$65,565
2.2	Net Profit from continuing operations	up	\$22,145	to	\$4,183
2.3	Net profit for the period attributable to members	up	\$22,145	to	\$4,183
2.4	Dividends (distributions)		Amount per security		Franked amount per security
	Final Dividend		\$0.005		Fully franked
	Previous corresponding period		NIL		NIL
2.5	The record date for determining entitlements to the dividends		21 November 2008		
2.6	See separate announcement entitled <i>Commentary on Results</i> for explanation on the above information				
3.	Income Statement – see accompanying preliminary financial statements				
4.	Balance sheet – see accompanying preliminary financial statements				
5.	Cash flow statement – see accompanying preliminary financial statements				

6. Dividends

The Directors of the company have resolved to pay a final dividend of 0.5 cents per share (2007 : Nil cents per share). The dividend will be paid on or around 15 December 2008 with a record date of 21 November 2008. As disclosed in the company's Explanatory Memorandum, dated 18 June 2008, new shares issued in relation to the acquisition of the Strides Asia business will not be eligible to participate in this dividend payment.

Based on the amount of shares on issue at 30 June 2008 of 138,524,994 shares (2007:139,258,328 shares), the proposed final dividend is \$692,625 (2007: \$nil). This amount has not been recognised as a liability at the year end in the accompanying financial statements.

7. Details of dividend or distribution reinvestment plans in operation

n/a

8. Net asset backing

	30 June 2008 cents	30 June 2007 cents
Net tangible assets per ordinary security	9.1	8.0

9. Control gained over entities during the financial year

n/a

10. Details of aggregate share of profits (losses) of associates and joint venture entities

n/a

11. Subsequent events

On August 1 2008 the Company announced the completion of the share purchase agreement between the company, Strides Arcolab Limited (Strides) and Linkace Limited (a subsidiary of Strides)

As part of the completion, the Company issued 83,730,909 fully paid ordinary shares to Linkace Limited. The issued shares rank equally with all existing fully paid shares, except they are not eligible to participate in the final dividend declared for the financial year 2008.

Effective as of August 1, 2008, the company took ownership of the Strides Asia operations and began operating as a multinational generic pharmaceutical and healthcare product business with sales in 9 countries across the Asia Pacific region under the brands of *Genepharm* and *Drug Houses of Australia*.

As a result of this transaction, Strides, through its subsidiary Linkace Limited, owns more than 50% of the shares in Ascent Pharmahealth Limited.

Following completion, the Company changed its name to Ascent Pharmahealth Limited and appointed two additional Board members. These new members hold senior executive positions within the Strides worldwide organisation

12. Commentary on the results for the period

See separate announcement entitled *Commentary on Results*.

13. Compliance Statement

The financial statements are in the process of being audited and are not likely to be subject to dispute or qualification.

Signed on behalf of the Board

Ascent Pharmahealth Limited (formerly Genepharma Australasia Limited):



Signed: Dennis Bastas
CEO & Managing Director

Date: 27 August 2008



Ascent Pharmahealth limited
ABN 52 107 340 367

(formerly Geneparm Australasia Limited)

Preliminary Final Report
For the Year ending 30 June 2008

Income Statement

	Notes	30 June 2008 \$'000	30 June 2007 \$'000
Net sales of goods		65,565	54,575
Cost of Sales		(40,804)	(32,773)
Gross profit		24,761	21,802
Other revenue	2	392	720
Sales and marketing expenses		(10,350)	(13,434)
Distribution expenses		(1,625)	(767)
Corporate Affairs expenses		(1,272)	(1,580)
Regulatory Affairs expenses		(1,297)	(1,284)
Occupancy expenses		(878)	(809)
Administration expenses		(3,055)	(3,189)
Other expenses	3	(325)	(364)
Finance costs	3	(1,227)	(1,087)
Impairment of intangible asset and write off of associated net assets and liabilities		-	(18,461)
Profit (loss) before related income tax expense		5,124	(18,454)
Income tax (expense) / benefit attributable to ordinary activities	4	(941)	492
Net profit (loss) for the period		4,183	(17,962)
Basic profit (loss) per share (cents per share)		3.0	(13.0)
Diluted profit (loss) per share (cents per share)		2.9	(13.0)

The Income Statement is to be read in conjunction with the notes to the financial statements.

Balance Sheet

	Notes	30 June 2008 \$'000	30 June 2007 \$'000
Current assets			
Cash assets	5	2,124	13,460
Receivables	6	15,580	12,295
Inventories	7	11,388	11,577
Other	8	1,670	609
Total current assets		30,762	37,941
Non-current assets			
Plant and equipment	9	1,853	1,411
Intangibles	10	61,665	61,701
Deferred tax assets		1,172	1,606
Total non-current assets		64,690	64,718
Total assets		95,452	102,659
Current liabilities			
Trade and other payables	11	12,105	15,651
Interest bearing liabilities	12	2,006	13,209
Income tax payable		603	496
Provisions	13	437	412
Total current liabilities		15,151	29,768
Non-current liabilities			
Interest bearing liabilities	12	5,940	-
Provisions	13	84	81
Total non-current liabilities		6,024	81
Total liabilities		21,175	29,849
Net assets		74,277	72,810
Equity			
Contributed equity	14	96,687	97,053
Reserves	15	2,517	2,198
Convertible notes – equity value (net of costs)		-	2,669
Accumulated losses	16	(24,927)	(29,110)
Total equity		74,277	72,810

The Balance Sheet is to be read in conjunction with the notes to the financial statements.

Statement of Changes in Equity

	Issued Capital \$000's	Retained losses \$'000	Convert- ible Notes \$000's	Other Reserves \$'000	Total \$'000
At 1 July 2006	46,896	(11,148)	-	1,736	37,484
Prior period profit after tax	-	(17,962)	-	-	(17,692)
Costs associated with share issues	(1,609)	-	-	-	(1,609)
Share based payments	-	-	-	462	462
Share issued	51,766	-	-	-	51,766
Convertible notes: equity value	-	-	2,669	-	2,669
At 30 June 2007	97,053	(29,110)	2,669	2,517	72,810
Current period profit after tax	-	4,183	-	-	4,183
Costs associated with share issues	(49)	-	-	-	(49)
Shares bought back	(356)	-	-	-	(356)
Share options expensed	-	-	-	18	18
Share issued via exercise of options	39	-	-	-	39
Convertible notes repaid: equity value	-	-	(2,669)	301	(2,368)
At 30 June 2008	96,687	(24,927)	-	2,517	74,277

Cash Flow Statement

	Notes	30 June 2008 \$'000	30 June 2007 \$'000
Cash flows from operating activities			
Receipts from customers		69,077	57,951
Payments to suppliers and employees		(68,497)	(53,696)
Interest received		160	688
Interest paid		(1,387)	-
Income taxes paid		(51)	(99)
Net cash flow from/(used in) operating activities	18	(698)	4,844
Cash flows from investing activities			
Purchase of plant and equipment		(1,019)	(830)
Payments for intangible assets		(884)	(1,015)
Costs associated with the acquisition of a business		(1,368)	(56,207)
Cash from acquired business		-	2,947
Net cash flow used in investing activities		(3,271)	(55,105)
Cash flows from financing activities			
Proceeds from the issue of shares		38	51,692
Transaction costs from issue of shares and convertible notes		(49)	(2,960)
Shares bought back		(356)	-
Repayment of convertible notes		(15,000)	-
Net proceeds from borrowings		8,000	-
Net cash flows from financing activities		(7,367)	48,732
Net increase / (decrease) in cash held		(11,336)	(1,529)
Cash at the beginning of the financial year		13,460	14,989
Cash at the end of the financial year		2,124	13,460

The Cash Flow Statement is to be read in conjunction with the notes to the financial statements.

Notes to and forming part of the Preliminary final report
for the period ending 30 June 2008

Note 1. Basis of Preparation

The financial report complies with Australian Accounting Standards, which include Australian equivalents to International Financial Reporting Standard ('AIFRS'). Compliance with AIFRS ensures that the financial report, comprising the financial statements and notes thereto, complies with International Financial Reporting Standards ('IFRS').

Notes	30 June 2008 \$'000	30 June 2007 \$'000
Note 2. Other revenue		
Interest	160	688
Other	232	32
	392	720
Note 3. Expenses		
(a) Other expenses		
Professional fees	-	289
Shares issued to staff	35	75
Goodwill expense arising from recognition of deferred tax asset	290	-
	325	364
(b) Finance costs		
Bank fees and charges	284	155
Interest	886	922
Bad Debts written off	57	8
	1,227	1,087
(c) Depreciation and amortisation		
Depreciation – plant and equipment	577	325
Amortisation of distribution agreement and distribution rights	-	2,404
Amortisation of dossier costs	460	342
Amortisation of supplier licence agreement	169	169
	1,206	3,240
(d) Lease payments included in income statement		
Minimum lease payments – operating lease	1,214	970
	1,214	970
(e) Employee benefits expense		
Wages and salaries	8,121	7,224
Defined contribution superannuation	678	581
Share-based payment expense	10	193
Other employee benefits expense	556	1,055
	9,365	9,053

Notes to and forming part of the preliminary final report
for the period ending 30 June 2008

Notes	30 June 2008 \$'000	30 June 2007 \$'000
Note 4.		
Numerical reconciliation between aggregate tax expense recognised in the income statement and tax expense calculated per statutory income tax rate.		
Accounting profit before income tax	5,124	18,454
At the statutory income tax rate of 30% (2007: 30%)	1,537	(5,536)
GAPE relationship write off	-	4,952
Amortisation of distribution agreement	-	721
Equity based payments	16	139
Interest on convertible note	23	150
Gain on convertible note	(65)	-
Amortisation of licences	-	81
Goodwill expense	87	-
Writeback of deferred tax liability	(290)	-
Recognition of unrealised tax losses	-	(1,232)
Prior period overs/ unders	(235)	-
Other	(132)	233
Income tax expense /(benefit) reported in income statement	941	(492)
Note 5 Cash Assets		
Cash at bank and on hand	2,124	3,643
Term deposit	-	9,817
	2,124	13,460
Note 6. Receivables – Current		
Trade receivables	15,093	12,243
Allowance for doubtful debts	(56)	(35)
Other receivables	543	87
	15,580	12,295
Note 7. Inventories		
Inventories on hand and in transit	11,687	11,993
Provision for obsolete stock	(299)	(415)
	11,388	11,578
Note 8. Other Current Assets		
Deposit	80	31
Prepayments	374	478
Acquisition costs	1,216	-
Other	-	100
	1,670	609

Notes to and forming part of the preliminary final
report for the period ending 30 June 2008

Notes	30 June 2008 \$'000	30 June 2007 \$'000
-------	---------------------------	---------------------------

Note 9. Plant and Equipment

Gross Carrying amount

Balance at 1 July	2,609	321
Acquired on acquisition of subsidiary	-	1,412
Additions	1,019	876
Balance at 30 June	3,628	2,609

Accumulated Depreciation

Balance at 1 July	(1,198)	(43)
Acquired on acquisition of subsidiary	-	(830)
Depreciation expense	(577)	(325)
Balance at 30 June	1,775	(1,198)

Net Book Value

	1,853	1,411
--	--------------	--------------

Note 10. Intangibles

Dossier costs	4,265	3,380
Accumulated amortisation	(1,092)	(631)
	3,173	2,749

Supplier Licence Agreement	1,185	1,186
Accumulated amortisation	(338)	(169)
	847	1,017

Trademarks	6,400	6,400
Goodwill on consolidation	51,245	51,535
	61,665	61,701

Note 11. Current Payables

Trade creditors and accruals	10,390	11,322
Other payables	1,046	3,945
Net GST payable	669	384
	12,105	15,651

Note 12. Interest Bearing Liabilities

Current

Convertible Notes	-	13,209
Loans	2,006	-
	2,026	13,209

Non Current

Loans	5,940	-
	5,940	-

Notes to and forming part of the preliminary final report
for the period ending 30 June 2008

	Notes	30 June 2008 \$'000	30 June 2007 \$'000
Note 13. Provisions			
<i>Current</i>			
Employee entitlements		437	412
		437	412
<i>Non Current</i>			
Employee entitlements		84	81
		84	81

Note 14 Contributed Equity

Reconciliation of movement in contributed equity

	30 June 2008		30 June 2007	
	No of Shares	Value A\$'000	No of Shares	Value A\$'000
Ordinary shares fully paid				
Balance at beginning of period	139,258,328	97,053	87,492,000	46,896
Shares issued via exercise of options	76,243	39	-	-
Shares issued via rights issue	-	-	51,691,600	51,691
Costs associated with share issues	-	(49)	-	(1,609)
Share Buy back	(809,577)	(356)	-	-
Shares issued to staff	-	-	74,728	75
	138,524,994	96,687	139,258,328	97,053

	Notes	30 June 2008 \$'000	30 June 2007 \$'000
Note 15. Reserves			
Share Option Reserve			
Balance at beginning of financial period		2,198	1,736
Options expensed		18	462
Balance at end of financial period		2,216	2,198
Transfer – residual Convertible notes reserve		301	
		2,517	2,198

Note 16. Accumulated losses

Balance at beginning of financial period	(29,110)	(11,148)
Current period profit (loss) attributed to the operations of Ascent Pharmahealth Limited and its controlled entities	4,183	(17,962)
Accumulated losses at the end of the financial period	(24,927)	(29,110)

Notes to and forming part of the preliminary final report
for the period ending 30 June 2008

Notes	30 June 2008 \$'000	30 June 2007 \$'000
-------	---------------------------	---------------------------

Note 17. Earnings Per Share

The following reflects the income and share data used in the calculations of basic and diluted earnings per share:

Net profit /(loss)	4,183	(17,962)
Earnings used in calculating basic and diluted earnings per share	4,183	(17,962)

Number of shares

Weighted average number of ordinary shares used in calculating basic earnings per share	138,819,229	137,662,293
---	-------------	-------------

Effect of dilutive securities:

Share options	4,520,805	5,324,671
---------------	-----------	-----------

Adjusted weighted average number of ordinary shares used in calculating diluted earnings per share	143,340,034	141,492,097
--	-------------	-------------

Note 18. Notes to the Statement of Cash Flows

Reconciliation of operating profit (loss) after income tax to net cash flows from operating activities	30 June 2008 \$'000	30 June 2007 \$'000
---	------------------------------------	------------------------------------

Net profit (loss) after income tax	4,183	(17,962)
<i>Adjustments for:</i>		
Write off of supplier distribution agreement and associated assets and liabilities	-	18,461
Depreciation and amortisation of non-current assets	577	325
Amortisation of intangible assets	629	2,915
Goodwill expense	290	
Shares capital issued and share options expensed	18	537
Gain on settlement of convertible note	(216)	-
Increment in interest expense on convertible note	88	-
Interest on convertible notes	(501)	924
Other items	-	14
<i>Changes in net assets and liabilities</i>		
(Increase)/decrease in assets		
- Trade and other receivable	(3,285)	(2,056)
- Inventories	190	(4,362)
- Other assets	155	(160)
- Deferred tax assets	585	(789)
Increase/(decrease) in liabilities		
- Trade and other payables	(3,546)	6,724
- Tax payable and deferred tax liabilities	107	215
- Provisions	28	58
Net cash (used in) / from operating activities	(698)	4,844